Prognostic impact of proton pump inhibitors for immunotherapy in advanced urothelial carcinoma.

ABSTRACT:

Objective

To evaluate the effects of the concomitant use of proton pump inhibitors (PPIs) and/or antibiotics (Abs) on oncological outcomes in patients with advanced urothelial carcinoma.

Patients and methods

We retrospectively evaluated 155 patients with advanced urothelial carcinoma who were treated with immune checkpoint inhibitors (ICIs) between August 2015 and April 2021. The concomitant use of PPI or Abs was defined as any PPI or Abs administered within 30 days before ICI initiation and during ICI therapy. The primary outcomes were the effect of PPI and/or Abs use on the objective response rate (ORR) and immune-related adverse events (irAEs). The secondary outcomes were the effects of PPI and/or Abs use on progression-free survival (PFS) and overall survival (OS) after

SUBMITTER: Okuyama Y 

PROVIDER: S-EPMC8988833 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature